查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018461

末期腎病市場：依治療方法、取得途徑和最終用戶分類－2026-2032年全球市場預測

End Stage Renal Disease Market by Treatment Modality, Access Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，末期腎功能衰竭市場價值將達到 610.4 億美元，到 2026 年將成長至 701.8 億美元，到 2032 年將達到 1,649.7 億美元，年複合成長率為 15.26%。

主要市場統計數據
基準年 2025 610.4億美元
預計年份：2026年 701.8億美元
預測年份 2032 1649.7億美元
複合年成長率 (%) 15.26%

全面概述正在重塑末期腎臟病 (ESRD) 醫療保健服務體系和相關人員優先事項的臨床和營運趨勢演變。

末期腎病 (ESRD) 帶來了一系列複雜的臨床、營運和經濟挑戰，這些挑戰波及整個醫療保健系統、醫療服務網路和患者群體。患者族群的老化和多種合併症盛行率的不斷上升，使得治療方法方案更加複雜，也更需要整合式照護路徑。同時，透析技術、血管通路、移植方案和數位療法等方面的技術進步正在改變臨床決策和醫療服務模式。這些變化既為臨床醫生、採購團隊、製造商和保險公司帶來了機遇，也帶來了壓力，因為他們必須在臨床療效、成本效益和醫療服務可近性之間取得平衡。

確定推動末期腎病 (ESRD)治療方法、供應鏈韌性、勞動力重組和以患者為中心的創新的關鍵系統性變革。

在末期腎病（ESRD）領域，一系列變革正在發生，其影響遠不止於臨床療效的提升，更在於重新定義醫療模式和相關人員關係。科技創新加速了居家治療方法和遠距監測平台的普及，減輕了病患就醫的負擔，並透過持續的數據流實現了早期療育。同時，政策轉變強調以價值為導向的治療結果，在與醫療服務提供者就合約和報銷進行談判時，更加重視護理協調、藥物依從性支持和療效評估。這些因素共同推動著更分散化、以病人為中心的醫療模式的形成。

分析 2025 年關稅措施對 ESRD 照護的籌資策略、製造地、供應鏈風險管理和臨床資本規劃的影響。

美國2025年實施的關稅政策對末期腎功能衰竭（ESRD）相關人員產生了顯著的下游影響，改變了醫療設備、耗材和藥品供應鏈的成本結構和籌資策略。進口關稅影響了透析機、一次性用品和血管通路裝置的採購決策，促使製造商和醫療機構重新評估區域製造地和長期供應商關係。為此，許多機構加快了近岸外包的步伐，並擴大了與國內契約製造製造商的合作，以降低跨境價格波動和前置作業時間風險的影響。

針對特定細分市場，深入了解治療方法、血管通路和護理環境之間的相互依存關係如何決定末期腎臟病服務的臨床路徑、營運要求和投資重點。

透過細分獲得的洞見揭示了治療方法、血管通路和護理環境選擇如何相互作用，從而塑造臨床路徑和營運需求。治療方法方案包括血液透析、腹膜透析和腎臟移植。血液透析進一步分為居家透析和機構透析模式，而腹膜透析則分為持續性移動腹膜透析（CAPD）和持續性循環腹膜透析（CCPD）。在腎臟移植路徑中，患者的預後取決於捐贈者來源（屍體捐贈或活體捐贈）。這些差異至關重要，因為每種治療方法及其子類別都會對醫療設備、病患教育、監測基礎設施和長期臨床追蹤產生不同的需求，從而影響採購、培訓和治療依從性支援的優先事項。

對美洲、歐洲、中東和非洲以及亞太地區的趨勢如何影響末期腎功能衰竭(ESRD) 護理模式的採用、基礎設施投資和政策主導進行區域分析。

區域趨勢對末期腎功能衰竭(ESRD) 管理的醫療服務模式、投資重點和監管方法有顯著影響。在美洲，醫療保健系統多種多樣，從單一支付模式到混合模式不等，這影響著報銷機制、居家照護的普及率以及私部門參與服務提供的程度。儘管該地區在醫療設備引進和遠距遠端醫療整合方面通常處於領先地位，但同時也面臨農村地區勞動力短缺的困境，這限制了醫療服務的可及性。政策討論和支付方的舉措正在國家和地方政府層面塑造著以價值為導向的醫療保健的資本配置和獎勵。

對一家領先的 ESRD 護理企業策略進行了深入概述，該策略整合了產品創新、綜合服務、供應鏈敏捷性和監管合規性。

在末期腎病（ESRD）生態系統中，各公司之間的競爭與合作正在塑造產品設計、服務交付模式和售後支援策略。產業相關人員正日益從純粹以產品為中心的模式轉向整合醫療設備、耗材、培訓、維護和數位監測的綜合服務包。這種轉變回應了醫療服務提供者對可預測治療結果的需求，以及支付方對可衡量、基於價值的指標的偏好。因此，能夠提供強力的臨床證據、全面的培訓計劃和可靠的現場服務能力的公司在合約談判中擁有明顯的優勢。

為領導者提供具體建議，以擴大家庭醫療保健、加強供應鏈、促進數位整合並影響政策，從而確保末期腎臟病 (ESRD) 的長期績效。

行業領導者需要採取果斷協調的措施，將不斷變化的證據和營運壓力轉化為永續的競爭優勢。首先，各機構應優先發展居家治療方法，並輔以完善的病患教育和遠距監測項目，以滿足病患需求並減輕系統負擔。這些投入應輔以清晰的臨床路徑和結果指標，以實現持續改善。其次，企業和醫療服務提供者必須透過近岸外包、多通路採購和檢驗的本地夥伴關係關係來實現供應鏈多元化，以降低關稅波動和物流中斷帶來的風險。

對嚴謹的多方法調查方法的描述，該方法結合了與主要相關人員的對話、文獻整合、案例研究、情境檢驗和專家諮詢檢驗。

這些研究結果是基於一項多方面研究方法，旨在交叉檢驗臨床證據、實踐和政策趨勢。一級資訊來源包括與臨床醫生、供應鏈經理、醫療系統高管和支付方的結構化訪談，以收集關於治療方法部署、准入管理和採購挑戰的實地觀點。二級資訊來源包括同行評審的臨床文獻、監管文件、臨床實踐指南和公共文件，檢驗臨床療效和監管趨勢。基於這些信息，研究人員進行了定性整合和主題分析，重點關注病患就醫路徑、醫療設備生命週期管理和服務模式的經濟效益。

總結性整合重點強調了臨床創新、營運韌性和協作策略之間的相互作用，這對於改善末期腎功能衰竭(ESRD) 的護理結果和獲得治療至關重要。

總之，末期腎功能衰竭（ESRD）的治療正處於一個轉折點，臨床創新、政策獎勵和營運限制相互交織，重塑著服務的提供和資金籌措方式。居家治療方法的日益普及，以及血管通路和監測技術的進步，為改善病患體驗和治療效果提供了實際的機會。然而，這些機會也伴隨著持續存在的挑戰，例如人員短缺、基礎設施不完善和供應鏈脆弱，需要製定周密的安寧療護策略來應對這些挑戰。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：末期腎病市場（依治療方法分類）

  • 血液透析
    • 家
    • 設施內部
  • 腹膜透析
    • 持續性移動腹膜透析
    • 持續性腹膜透析
  • 移植
    • 腦死捐贈者
    • 活體捐贈者

第9章：末期腎病的市場進入方法

  • 動靜脈瘻管
  • 中央靜脈導管
  • 合成接枝

第10章 末期腎病市場：依最終用戶分類

  • 透析中心
  • 居家照護設施
  • 醫院

第11章 末期腎病市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 末期腎病市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 末期腎病市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國末期腎臟病市場

第15章：中國末期腎病市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AngioDynamics Inc.
  • Asahi Kasei Corporation
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Cantel Medical Corp.
  • DaVita Inc.
  • Dialysis Clinic Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • Medtronic plc
  • Nipro Corporation
  • NxStage Medical Inc.
  • Outset Medical Inc.
  • Rockwell Medical Inc.
  • Satellite Healthcare Inc.
  • US Renal Care Inc.
Product Code: MRR-DA46DD749C68

The End Stage Renal Disease Market was valued at USD 61.04 billion in 2025 and is projected to grow to USD 70.18 billion in 2026, with a CAGR of 15.26%, reaching USD 164.97 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 61.04 billion
Estimated Year [2026] USD 70.18 billion
Forecast Year [2032] USD 164.97 billion
CAGR (%) 15.26%

Comprehensive introduction to the evolving clinical and operational dynamics that are reshaping End Stage Renal Disease care delivery and stakeholder priorities

End Stage Renal Disease (ESRD) poses a complex blend of clinical, operational, and economic challenges that reverberate across healthcare systems, provider networks, and patient communities. Patient populations are aging and increasingly present multiple comorbidities, which complicates treatment selection and intensifies demand for integrated care pathways. Concurrently, technological advances in dialysis modalities, vascular access, transplantation protocols, and digital therapeutics are reshaping clinical decision-making and care delivery models. These changes create both opportunities and pressures for clinicians, procurement teams, manufacturers, and payers who must balance clinical outcomes with affordability and access.

In recent years, patient preferences have shifted toward treatments that maximize quality of life and minimize disruption, prompting a strategic reassessment of in-center care versus home-based therapies. Regulatory agendas and reimbursement frameworks have begun to reflect that shift, incentivizing modalities and service designs that demonstrate clinical effectiveness and cost containment. At the same time, workforce constraints and supply chain fragilities are forcing providers and vendors to rethink sourcing, logistics, and training investments. As a result, stakeholders increasingly prioritize solutions that deliver clinical reliability, flexible delivery models, and integrated support services.

This executive summary synthesizes the essential trends and strategic implications shaping ESRD care. It emphasizes the intersection of clinical innovation, operational resilience, and stakeholder alignment, and it frames the questions leaders must answer to sustain high-quality care for growing, complex patient cohorts. By foregrounding patient-centric approaches and system-level efficiencies, the summary offers a practical orientation for leaders seeking to navigate near-term disruptions while positioning their organizations for sustained clinical and economic performance.

Identification of the major systemic transformations in ESRD care that are driving modality shifts, supply chain resilience, workforce reconfiguration, and patient-centered innovation

The ESRD landscape is undergoing a sequence of transformative shifts that extend beyond incremental clinical improvements to redefine care models and stakeholder relations. Technological innovation has accelerated the adoption of home modalities and remote monitoring platforms, reducing patient travel burden and enabling earlier intervention through continuous data streams. Simultaneously, policy shifts emphasize value-based outcomes, which elevates the role of care coordination, adherence support, and outcome measurement in provider contracting and reimbursement conversations. These forces together are driving a more decentralized, patient-centered model of care.

Workforce pressures and evolving clinician roles are also reshaping operational models. Nephrology teams are reallocating tasks through multidisciplinary care pathways and expanding nurse-led and telehealth-driven services to maintain access and quality. Supply chain resilience has become a core strategic priority, prompting investment in local manufacturing capabilities, diversified supplier networks, and inventory management systems that can withstand geopolitical and logistic shocks. Moreover, innovation in vascular access techniques and transplant management is altering long-term patient trajectories, thereby influencing capacity planning for dialysis centers and transplant programs.

Finally, patient engagement and shared decision-making are advancing rapidly as digital literacy increases among older adults and caregivers. Providers and vendors that embed usability, education, and psychosocial supports into product and service designs achieve higher adherence and better outcomes. Taken together, these shifts indicate an ecosystem moving toward integrated care pathways, technology-enabled home options, and risk-sharing arrangements that reward demonstrable improvements in patient-centric metrics.

Analysis of how 2025 tariff measures have reshaped procurement strategies, manufacturing footprints, supply chain risk management, and clinical capital planning for ESRD care

The implementation of United States tariffs in 2025 has created material downstream effects for ESRD stakeholders by altering cost structures and procurement strategies across the device, consumable, and pharmaceutical supply chains. Import levies have influenced sourcing decisions for dialysis machines, disposables, and access devices, prompting manufacturers and providers to re-evaluate regional manufacturing footprints and long-term supplier relationships. In response, many organizations accelerated nearshoring initiatives and expanded partnerships with domestic contract manufacturers to mitigate exposure to cross-border price volatility and lead-time risks.

Procurement teams faced greater complexity as total landed costs became less predictable, which in turn shifted emphasis from unit price alone to broader procurement metrics such as delivery reliability, quality assurance, and supplier diversification. These shifts also affected negotiation dynamics with original equipment manufacturers and distributors, who increasingly offered bundled service and maintenance contracts to preserve stable revenue streams while providing clients with predictable lifecycle support. In parallel, clinicians and hospital administrators experienced indirect impacts through altered purchasing cycles and delayed capital investments, as organizations assessed the financial implications of higher equipment and consumable costs.

On the innovation front, R&D roadmaps adjusted to prioritize modular, locally assemblable platforms that reduce tariff exposure and support flexible production scaling. Policy engagement intensified as industry groups and health system leaders advocated for tariff exemptions or targeted relief for critical medical supplies to preserve access and affordability for vulnerable patient populations. Overall, the cumulative impact of 2025 tariff measures has been to refocus strategic planning on supply chain agility, procurement sophistication, and policy advocacy to safeguard continuity of care for ESRD patients.

Segment-driven insights into how modality, vascular access, and care setting interdependencies define clinical pathways, operational demands, and investment priorities for ESRD services

Insights derived from segmentation reveal how modality choice, vascular access, and care setting interlock to shape clinical pathways and operational requirements. Treatment Modality considerations encompass Hemodialysis, Peritoneal Dialysis, and Transplant, with Hemodialysis further differentiated between Home and Incenter delivery models, and Peritoneal Dialysis separated into Continuous Ambulatory Peritoneal Dialysis and Continuous Cycling Peritoneal Dialysis; Transplant pathways distinguish patient journeys by Deceased Donor and Living Donor sources. These distinctions matter because each modality and sub-modality drives different needs for capital equipment, patient education, monitoring infrastructure, and long-term clinical follow-up, thereby influencing procurement, training, and adherence support priorities.

Access Type segmentation clarifies clinical and logistical trade-offs across Arteriovenous Fistula, Central Venous Catheter, and Synthetic Graft options. Vascular access choice directly affects complication rates, hospitalization risk, and the intensity of maintenance protocols, which in turn shapes staffing models and ancillary service demand. Providers must therefore align vascular access programs with modality strategies to optimize patient outcomes and reduce avoidable utilization.

End User segmentation, which examines Dialysis Centers, Home Care Settings, and Hospitals, highlights divergent operational models and service expectations. Dialysis centers emphasize throughput, standardized protocols, and bundled service offerings, whereas home care settings prioritize patient training, remote monitoring, and supply delivery logistics. Hospitals require integrated acute care pathways and rapid escalation mechanisms for complications. Understanding how these segments interact enables leaders to design modality-specific service bundles, tailor clinician training, and prioritize investments that support both clinical effectiveness and patient experience.

Regional analysis of how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics influence adoption, infrastructure investment, and policy-driven ESRD care models

Regional dynamics materially influence care delivery choices, investment priorities, and regulatory approaches to ESRD management. In the Americas, healthcare systems vary from single-payer to mixed models, which affects reimbursement levers, adoption rates of home modalities, and private-sector participation in service delivery. This region often leads in device adoption and telehealth integration but also faces concentrated workforce shortages in rural areas that constrain access. Policy debates and payer initiatives shape capital allocation and incentives for value-based care across national and subnational jurisdictions.

Europe, Middle East & Africa present a heterogeneous mix of regulatory environments and infrastructure capacity that drives divergent adoption patterns. In higher-income European markets, rigorous clinical standards and comprehensive reimbursement frameworks support innovation uptake and robust transplantation programs, while emerging EMEA markets confront infrastructure gaps, limited dialysis capacity, and financing constraints that require scalable, low-resource solutions. Cross-border procurement and regional manufacturing hubs play increasing roles in improving supply reliability and cost efficiency.

Asia-Pacific combines rapidly growing demand, diverse payer structures, and a strong manufacturing base that supports both domestic production and export opportunities. Many health systems in the region are investing in home care models and digital platforms to extend access across urban and peri-urban populations, while also balancing the need to expand transplant infrastructure and workforce training. In each region, stakeholders must tailor strategies to local policy drivers, infrastructure realities, and demographic trends to ensure sustainable service delivery and equitable patient access.

Insightful overview of company strategies that blend product innovation, integrated services, supply chain agility, and regulatory excellence to lead in ESRD care

Competitive and collaborative behaviors among companies active in the ESRD ecosystem are shaping product design, service delivery models, and aftermarket support strategies. Industry participants are increasingly moving from a purely product-centric orientation to integrated service bundles that combine devices, consumables, training, maintenance, and digital monitoring. This shift responds to provider demand for predictable outcomes and to payer interest in measurable, value-based metrics. As a result, firms that can demonstrate robust clinical evidence, comprehensive training programs, and reliable field service capabilities gain a distinct advantage in contracting discussions.

Strategic partnerships, licensing arrangements, and co-development initiatives are becoming more common as companies seek to accelerate time-to-market for incremental innovations while sharing development risk. Contract manufacturing and regional assembly strategies are also expanding to reduce tariff exposure and improve lead times. Firms that invest in interoperable software and open-data approaches position themselves to participate in care networks and population health initiatives. Additionally, aftermarket services-ranging from consumable supply logistics to predictive maintenance and remote troubleshooting-are emerging as meaningful differentiators that influence customer retention and lifetime value.

Finally, companies that prioritize regulatory excellence and health economics evidence generation improve their access to premium procurement pathways and payer negotiations. The most resilient firms pair strong clinical pipelines with scalable service models and agile supply chains to meet the evolving needs of providers and patients in diverse care settings.

Actionable recommendations for leaders to scale home modalities, strengthen supply chains, advance digital integration, and influence policy to secure long-term ESRD performance

Industry leaders must take decisive, coordinated steps to translate evolving evidence and operational pressures into sustainable competitive advantage. First, organizations should prioritize expansion of home-based modalities alongside robust patient education and remote monitoring programs to align with patient preferences and reduce system-level burdens. Such investments should be accompanied by clear clinical pathways and outcome metrics that enable continual improvement. Second, firms and providers must diversify supply chains through nearshoring, multi-sourcing, and validated local partnerships to reduce exposure to tariff fluctuations and logistic disruptions.

Third, stakeholders should pursue interoperable digital platforms that integrate device telemetry, electronic health records, and patient-reported outcomes to support proactive care management and value-based contracting. Fourth, workforce development is critical: invest in scalable training programs that upskill nurses, technicians, and care coordinators to support home therapies and telehealth-enabled workflows. Fifth, engage proactively with policymakers and payers to shape reimbursement frameworks that reward demonstrated improvements in patient-centered outcomes, access, and long-term cost efficiencies. Finally, adopt a portfolio approach to innovation that balances near-term operational improvements with longer-term investments in transplant support, vascular access innovation, and minimally invasive technologies.

By implementing these actions in a coordinated manner, leaders can improve clinical outcomes, protect margins against external shocks, and position their organizations for sustained leadership as care models continue to evolve.

Explanation of a rigorous multi-method research methodology combining primary stakeholder engagement, literature synthesis, case studies, scenario testing, and expert advisory validation

The research underpinning these insights draws on a multi-method approach designed to triangulate clinical evidence, operational practice, and policy developments. Primary sources included structured engagements with clinicians, supply chain managers, health system executives, and payers to capture frontline perspectives on modality adoption, access management, and procurement challenges. Secondary sources encompassed peer-reviewed clinical literature, regulatory filings, clinical practice guidelines, and public policy documents to validate clinical efficacy and regulatory trajectories. These inputs informed qualitative synthesis and thematic analysis focused on patient pathways, device life-cycle management, and service model economics.

To ensure robustness, the methodology incorporated targeted case studies of exemplar provider systems and suppliers that have implemented home dialysis scale-ups, integrated remote monitoring, or resilient procurement strategies. Scenario analysis explored plausible supply chain and policy developments to stress-test strategic options, while an advisory panel of clinical and operational experts reviewed findings and recommended refinements. Data integrity measures included cross-validation of procurement and regulatory data points, careful documentation of interview protocols, and iterative reconciliation of stakeholder feedback to minimize bias and ensure relevance across care settings.

This layered approach balances deep qualitative insight with rigorous documentary evidence, producing findings that are actionable for clinicians, administrators, and commercial stakeholders seeking to improve patient outcomes and operational resilience in ESRD care.

Conclusive synthesis emphasizing the interplay of clinical innovation, operational resilience, and collaborative strategies required to improve ESRD care outcomes and access

In synthesis, End Stage Renal Disease care is at an inflection point where clinical innovation, policy incentives, and operational constraints converge to reshape how services are delivered and financed. The growing emphasis on home-based modalities, coupled with advances in vascular access and monitoring technologies, creates tangible opportunities to improve patient experience and outcomes. However, these opportunities coexist with persistent challenges, including workforce shortages, infrastructure gaps, and supply chain vulnerabilities that require deliberate mitigation strategies.

Leaders who proactively realign procurement, clinical pathways, and digital integration will be better positioned to manage external shocks and deliver on value-based objectives. Equally important is the need for collaborative approaches that bring together clinicians, payers, manufacturers, and patient advocates to design pragmatic solutions that scale across diverse settings. By focusing on modular, interoperable solutions, strengthening local manufacturing and supplier networks, and rigorously measuring patient-centered outcomes, stakeholders can enhance access and resilience while preserving clinical excellence.

Ultimately, the pathway forward requires coordinated investment and disciplined execution. Organizations that integrate these insights into strategic plans will not only improve care for patients living with ESRD but also create sustainable operating models that withstand market and policy volatility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. End Stage Renal Disease Market, by Treatment Modality

  • 8.1. Hemodialysis
    • 8.1.1. Home
    • 8.1.2. Incenter
  • 8.2. Peritoneal Dialysis
    • 8.2.1. Continuous Ambulatory Peritoneal Dialysis
    • 8.2.2. Continuous Cycling Peritoneal Dialysis
  • 8.3. Transplant
    • 8.3.1. Deceased Donor
    • 8.3.2. Living Donor

9. End Stage Renal Disease Market, by Access Type

  • 9.1. Arteriovenous Fistula
  • 9.2. Central Venous Catheter
  • 9.3. Synthetic Graft

10. End Stage Renal Disease Market, by End User

  • 10.1. Dialysis Centers
  • 10.2. Home Care Settings
  • 10.3. Hospitals

11. End Stage Renal Disease Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. End Stage Renal Disease Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. End Stage Renal Disease Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States End Stage Renal Disease Market

15. China End Stage Renal Disease Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. AngioDynamics Inc.
  • 16.6. Asahi Kasei Corporation
  • 16.7. B. Braun Melsungen AG
  • 16.8. Baxter International Inc.
  • 16.9. Cantel Medical Corp.
  • 16.10. DaVita Inc.
  • 16.11. Dialysis Clinic Inc.
  • 16.12. Fresenius Medical Care AG & Co. KGaA
  • 16.13. Medtronic plc
  • 16.14. Nipro Corporation
  • 16.15. NxStage Medical Inc.
  • 16.16. Outset Medical Inc.
  • 16.17. Rockwell Medical Inc.
  • 16.18. Satellite Healthcare Inc.
  • 16.19. U.S. Renal Care Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL END STAGE RENAL DISEASE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL END STAGE RENAL DISEASE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA END STAGE RENAL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY INCENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY INCENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY INCENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS AMBULATORY PERITONEAL DIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS AMBULATORY PERITONEAL DIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS AMBULATORY PERITONEAL DIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS CYCLING PERITONEAL DIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS CYCLING PERITONEAL DIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CONTINUOUS CYCLING PERITONEAL DIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DECEASED DONOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DECEASED DONOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DECEASED DONOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY LIVING DONOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY LIVING DONOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY LIVING DONOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ARTERIOVENOUS FISTULA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ARTERIOVENOUS FISTULA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY ARTERIOVENOUS FISTULA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY CENTRAL VENOUS CATHETER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY SYNTHETIC GRAFT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY SYNTHETIC GRAFT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY SYNTHETIC GRAFT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY DIALYSIS CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. GCC END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GCC END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 120. GCC END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 121. GCC END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 122. GCC END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 123. GCC END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. GCC END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. G7 END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. G7 END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 141. G7 END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 142. G7 END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 143. G7 END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 144. G7 END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. G7 END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. NATO END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 148. NATO END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 149. NATO END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 150. NATO END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 151. NATO END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. NATO END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL END STAGE RENAL DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA END STAGE RENAL DISEASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY HEMODIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY PERITONEAL DIALYSIS, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY TRANSPLANT, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY ACCESS TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA END STAGE RENAL DISEASE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)